Hexagon Capital Partners’s Relmada Therapeutics RLMD Stock Holding History

Hexagon Capital Partners’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,000	Closed	-$1.08K	–	1353
2025 Q1	$1.08K	Hold	4,000	–	–	﹤0.01%	1534
2024 Q4	$2.08K	Hold	4,000	–	–	﹤0.01%	1407
2024 Q3	$13K	Hold	4,000	–	–	﹤0.01%	841
2024 Q2	$12K	Hold	4,000	–	–	﹤0.01%	820
2024 Q1	$18.6K	Hold	4,000	–	–	﹤0.01%	696
2023 Q4	$16.6K	Hold	4,000	–	–	﹤0.01%	702
2023 Q3	$12K	Hold	4,000	–	–	﹤0.01%	695
2023 Q2	$9.84K	Buy	4,000 +2,400	+150%	+$6.63K	﹤0.01%	753
2023 Q1	$3.62K	Hold	1,600	–	–	﹤0.01%	949
2022 Q4	$5.58K	Hold	1,600	–	–	﹤0.01%	888
2022 Q3	$59K	Hold	1,600	–	–	0.02%	344
2022 Q2	$30K	Hold	1,600	–	–	0.01%	455
2022 Q1	$43K	Hold	1,600	–	–	0.01%	394
2021 Q4	$36K	Hold	1,600	–	–	0.01%	404
2021 Q3	$42K	Hold	1,600	–	–	0.01%	368
2021 Q2	$51K	Hold	1,600	–	–	0.01%	323
2021 Q1	$56K	Hold	1,600	–	–	0.02%	293
2020 Q4	$51K	Hold	1,600	–	–	0.02%	266
2020 Q3	$47K	Buy	+1,600	New	+$61.8K	0.02%	262

Other funds holding RLMD

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Hexagon Capital Partners's RLMD Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Relmada Therapeutics (RLMD) in Q2 2025, closing a stake of 4,000 shares — an estimated $1.08K sold.

Hexagon Capital Partners first reported a position in RLMD in Q3 2020 and held it in 19 quarters. The position peaked at $59K in Q3 2022. 50 funds tracked by Wall St. Rank hold RLMD as of Q2 2025.

Hexagon Capital Partners reported no remaining Relmada Therapeutics position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 4,000 Relmada Therapeutics shares in Q2 2025, an estimated $1.08K.
Hexagon Capital Partners first reported a position in Relmada Therapeutics in Q3 2020 and held it in 19 quarters.
Hexagon Capital Partners's Relmada Therapeutics position peaked at $59K in Q3 2022.
50 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.